FDA Expands Eli Lilly's Mounjaro Approval to Cut Heart Attack and Stroke Risk
Indianapolis, Friday, 28 August 2026.
The FDA approved Eli Lilly’s Mounjaro to reduce major cardiovascular risks in adults with type 2 diabetes after trials showed an 8% lower risk of events compared to Trulicity.
FDA Expands Eli Lilly’s Mounjaro Approval to Cut Heart Attack and Stroke Risk
Eli Lilly and Company (NYSE: LLY) announced on 27 August 2026 that the U.S. Food and Drug Administration (FDA) approved a new indication for Mounjaro (tirzepatide) [1][2]. The approval allows the medication to be used to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [1]. This label expansion significantly broadens the clinical utility and market potential for Eli Lilly’s blockbuster drug [1]. The decision reinforces Eli Lilly’s competitive position against Novo Nordisk in the metabolic and cardiovascular therapeutic markets [1]. Heart disease remains the leading cause of death for people with type 2 diabetes [2]. Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health, stated that the company set a higher bar by testing Mounjaro against a GLP-1 medicine with proven cardiovascular benefit [2].
Clinical Trial Results and Methodology
The approval was supported by the SURPASS-CVOT trial, the largest and longest tirzepatide study conducted to date [1]. The study involved more than 13,000 participants across 30 countries over a period exceeding 4.5 years [2]. Results demonstrated that Mounjaro was non-inferior to Trulicity (dulaglutide), showing an 8% lower rate of major adverse cardiovascular events (MACE-3) [3]. The estimated hazard ratio for the time to first MACE was 0.92 with a 95.3% confidence interval of 0.83 to 1.01 [1]. Mounjaro is a dual GIP and GLP-1 hormone receptor agonist, whereas Trulicity is a GLP-1 receptor agonist [4]. Both medications are administered subcutaneously once weekly for adults and children 10 years of age and older with type 2 diabetes [1].
Market Dynamics and Competitive Context
This approval places Eli Lilly in direct competition with Novo Nordisk, which previously secured FDA approval for Wegovy for cardiovascular risk reduction in adults with heart disease and obesity on 8 March 2024 [3]. In 2025, the FDA also approved Novo Nordisk’s Rybelsus to reduce the risk of serious heart events in diabetic patients [5]. Both companies are seeking to expand the reach of their GLP-1 based medications into broader cardiovascular conditions [5]. Financially, the demand for Mounjaro has been substantial, with sales increasing 91% to reach $9.94 billion during the second quarter [5]. This growth is driven by strong demand volumes in global markets [5]. The expansion into cardiovascular risk reduction is expected to further impel the billion-dollar dispute between Lilly and its rival Novo Nordisk in new health treatments [5].
Safety Profile and Administration Guidelines
Mounjaro is available as a pre-filled single-dose pen in dosage strengths ranging from 2.5 mg to 15 mg per 0.5 mL injection [1]. Serious side effects associated with the medication include pancreatitis, hypoglycemia, and severe stomach issues such as gastroparesis [2]. Patients are advised that contraceptive efficacy may be reduced while using Mounjaro, requiring alternative birth control for four weeks after initiation and dose escalations [2]. The FDA approval marks a significant milestone occurring on 27 August 2026, according to Eli Lilly’s investor relations [1]. While some reports date the announcement to 28 August 2026, the company confirms the regulatory decision was finalized previously [5]. This timeline clarity ensures investors and patients understand the regulatory status as of late August 2026 [4].